Ensysce Biosciences (NASDAQ:ENSC) Issues Earnings Results

Ensysce Biosciences (NASDAQ:ENSC) posted its quarterly earnings data on Friday. The company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.44), Zacks reports. Ensysce Biosciences had a negative net margin of 88.76% and a negative return on equity of 167.23%. The firm had revenue of $0.49 million during the quarter.

Ensysce Biosciences Stock Performance

Shares of NASDAQ:ENSC traded down $0.01 during midday trading on Friday, reaching $2.06. The company had a trading volume of 65,859 shares, compared to its average volume of 71,492. The company has a fifty day simple moving average of $2.22 and a two-hundred day simple moving average of $2.21. The firm has a market cap of $6.12 million, a price-to-earnings ratio of -0.51 and a beta of 1.14. Ensysce Biosciences has a 1-year low of $1.62 and a 1-year high of $11.13.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ensysce Biosciences stock. Virtu Financial LLC acquired a new stake in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,222 shares of the company’s stock, valued at approximately $34,000. Virtu Financial LLC owned about 0.48% of Ensysce Biosciences at the end of the most recent quarter. 5.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ENSC has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Ensysce Biosciences to a “hold” rating in a research note on Saturday, October 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Ensysce Biosciences has an average rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.